Bank of America Issues Pessimistic Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price reduced by stock analysts at Bank of America from $54.00 to $32.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s price objective would indicate a potential upside of 26.78% from the stock’s current price.

Several other equities research analysts have also issued reports on the company. Scotiabank dropped their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a research report on Monday, July 28th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Thursday, November 13th. Leerink Partners upgraded shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and reduced their price target for the stock from $40.00 to $34.00 in a research report on Thursday. Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Zacks Research raised shares of Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $36.00.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO opened at $25.24 on Thursday. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -3.61 and a beta of 0.89. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $62.45. The stock has a 50-day simple moving average of $39.91 and a 200 day simple moving average of $36.79.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.93) by $0.15. The firm had revenue of $12.90 million for the quarter, compared to analysts’ expectations of $10.49 million. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.Agios Pharmaceuticals’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $16.22 earnings per share. On average, equities research analysts forecast that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 3,302 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $43.92, for a total value of $145,023.84. Following the sale, the insider owned 61,727 shares in the company, valued at approximately $2,711,049.84. This trade represents a 5.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Theodore James Jr. Washburn sold 8,546 shares of Agios Pharmaceuticals stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $36.87, for a total value of $315,091.02. Following the sale, the insider directly owned 868 shares in the company, valued at approximately $32,003.16. This trade represents a 90.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 16,099 shares of company stock worth $620,092 in the last ninety days. 4.30% of the stock is owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC bought a new stake in Agios Pharmaceuticals during the 1st quarter valued at $40,000. First Horizon Corp acquired a new position in shares of Agios Pharmaceuticals during the third quarter valued at $45,000. CWM LLC raised its stake in shares of Agios Pharmaceuticals by 150.2% during the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 996 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Agios Pharmaceuticals by 16.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 320 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Agios Pharmaceuticals in the third quarter worth about $79,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.